Cheryl Ho, MD, FRCP(C)
Cheryl Ho, MD, FRCPC
Clinical Associate Professor
University of British Columbia
British Columbia Cancer
Cheryl Ho, MD is a medical oncologist at BC Cancer and Clinical Associate Professor at the University of British Columbia. Her clinical practice focuses on thoracic and head & neck malignancies. Dr. Ho evaluates the impact of therapies proven in clinical trials in the real world through population-based analysis. Her current focus is on developing a learning health care system with a real-world data evidence-generation framework to inform healthcare decision-makers.
Barbara Melosky, MD, FRCP(C)
Professor of Medicine, UBC
Medical Oncologist, BC Cancer
Dr. Melosky is a Professor of Medicine at the University of British Columbia and a Medical Oncologist in Vancouver at BC Cancer. She graduated from medical school at the University of Manitoba and did a residency in internal medicine and an oncology fellowship at the University of British Columbia. Dr. Melosky specializes in the field of thoracic malignancy. She sits on the Executive Lung Site Committee for CCTG Canadian Clinical Trials Group.
Her main focus of clinical trials is on EGFR inhibitors; she is published in this area and is considered a national and international expert. Dr. Melosky has chaired the Canadian Lung Cancer Conference for the last 12 years, which is attended by over 350 participants. She chairs and organized the multi-disciplinary Lung Cancer Journal Club three times yearly. She is chair and created the British Columbia Lung Cancer Biobank.
She is also the chairperson of the Colorectal Screening Program of British Columbia and has a special interest in EGFR receptors and management of side effects.
Randeep Sangha, MD, FRCPC
Medical Oncologist, Cross Cancer Institute
Associate Professor, University of Alberta
Dr. Sangha is an Associate Professor in the Department of Oncology at the University of Alberta and Medical Oncologist at the Cross Cancer Institute, Edmonton, AB. He is the Provincial Lead for the Alberta Lung Cancer Program.
Dr. Sangha received his medical degree at the University of Alberta and subsequently specialized in Internal Medicine and Medical Oncology. He completed two years of post-fellowship training in thoracic oncology at the University of California, Davis Comprehensive Cancer Center.
His academic, clinical, and educational activities revolve around thoracic and hematological malignancies. He is also experienced in Investigational New Drug (Phase I) development and is actively involved in the Phase I clinical trials program at the Cross Cancer Institute.
Devin Schellenberg, MD, FRCS(C)
Clinical Associate Professor – UBC
Department Head, Radiation Oncology
BC Cancer – Surrey Centre
Dr. Devin Schellenberg is a radiation oncologist practicing at the BC Cancer Surrey Centre. He is currently the department head of radiation oncology at Surrey Centre and is one of the leaders in the British Columbia stereotactic radiation working group.
His radiation oncology residency was carried out at Princess Margaret Hospital in Toronto and the BC Cancer Agency, after which he completed a fellowship in stereotactic body radiation therapy at Stanford University in 2007.
His present research is focused on the use of novel imaging modalities in radiation therapy.